Providers/Grant Support
This educational activity is supported by an educational grant from Bristol Myers Squibb
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of hematologists and hematology oncologists treating patients with multiple myeloma.
Program Overview
This Expert Roundtable featuring Joshua Richter, Hira Mian, and Stefan Knop has been developed to enhance understanding of the evolving treatment landscape in multiple myeloma.
This accredited educational activity explores the potential role of CELMoDs, including patient identification, treatment access considerations, adverse event management, and the evolving role of MRD in treatment decision-making.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the current treatment landscape in multiple myeloma, including best practices in treatment sequencing and shared decision-making (Moore’s level 3A)
- Evaluate where CELMoDs could fit into the current multiple myeloma treatment paradigm based on ongoing clinical trials, considering impact on different clinical settings (Moore’s level 3B)
- Select appropriate adverse event management strategies during potential use of CELMoDs in the treatment of multiple myeloma, considering at-home administration, monitoring, and patient characteristics (Moore’s level 4)
- Evaluate how increasing endorsement of MRD as a clinical endpoint in multiple myeloma may influence clinical trial design, regulatory pathways, and real-world treatment decisions (Moore’s level 3B)
Faculty
Joshua Richter - Activity Chair
Joshua Richter, MD, FACP, is an Associate Professor of Medicine, Hematology and Oncology in the Myeloma Division at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. He also serves as the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai.
Dr. Richter completed his undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College. He completed his residency at St. Vincent's Hospital, New York Medical College, and his hematology/ oncology fellowship at Yale Cancer Center. After completing his fellowship he worked in the myeloma division at the John Theurer Cancer Center, Hackensack University Medical Center. In 2018, he joined the Myeloma Division at Mount Sinai Hospital.
Dr. Richter has published in numerous oncology journals including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology. His clinical interests are in immunotherapy, multifunctional antibodies, and precision medicine.
Stefan Knop
Stefan Knop, MD, is Chair of the Department of Hematology and Medical Oncology at Nuremberg General Hospital and Paracelsus Medical School in Nuremberg, Germany. He previously served as Head of the Division of Hematology at Würzburg University Hospital and as Coordinator of the Wilhelm Sander Myeloma Unit at the University Medical Center Würzburg. He has also held academic appointments at the Julius Maximilians University of Würzburg, where he was appointed Full Professor of Medicine in 2020.
Prof. Knop completed his medical and doctoral training at Eberhard Karls University in Tübingen where he holds board certifications in Internal Medicine and in Hematology and Medical Oncology.
His research interests in plasma cell dyscrasias include genomic studies, molecular imaging, and minimal residual disease. Prof. Knop has published widely in the field of hemato-oncology, with more than 125 articles in journals such as the European Journal of Haematology, Lancet Oncology, Leukemia, Nature Cancer, and Nature Medicine.
Hira Mian
Hira Mian, MD, MSc, FRCPC, is a hematologist and Associate Professor in the Department of Oncology at McMaster University in Hamilton, Ontario, Canada, where she is the ArcelorMittal Dofasco Chair in Cancer Therapeutics Research. She is also the Multiple Myeloma Disease Site Lead at the Juravinski Cancer Centre in Hamilton.
Dr. Mian’s program integrates clinical trials with health services and outcomes research to improve treatment and supportive care for people living with multiple myeloma, especially older adults and those living with frailty. Her work examines how therapies perform in routine practice, how symptom burden and functional status affect outcomes, and how to design and deliver trials that better reflect real‑world patients.
Dr. Mian contributes to national and international collaborations in myeloma research and helps to translate emerging evidence into practice.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Joshua Richter, MD, FACP
Speaker bureau fees or honoraria for non-CME from Adaptive Biotechnologies, Bristol Myers Squibb, Janssen, Sanofi, and Pfizer.
Advisory board or consultancy fees from AbbVie, Bristol Myers Squibb, Forus, Genentech, Janssen, Karyopharm, Kite/Arcellx, Menarini, Pfizer, Regeneron, Sanofi, Takeda, and UB Therapeutics.
Stefan Knop, MD
Speaker bureau fees or honoraria for non-CME from BeOne, Bristol Myers Squibb, Molecular Partners, Oncopeptides, Pfizer, and Sanofi.
Advisory board or consultancy fees from BeOne, Bristol Myers Squibb, Molecular Partners, Oncopeptides, Pfizer, and Sanofi.
Grant/research support from Johnson & Johnson and Pfizer.
Hira Mian, MD, MSc, FRCPC
Speaker bureau fees or honoraria for non-CME from Amgen, Bristol Myers Squibb, Forus, GSK, Janssen, Pfizer, Sanofi, and Takeda.
Advisory board or consultancy fees from Amgen, Bristol Myers Squibb, Forus, GSK, Janssen, Pfizer, Sanofi, and Takeda.
Grant/research support from Janssen. Employee/ Owner at Hamilton Health Sciences.
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for the participant to download.
Course Viewing Requirements
Supported Browsers:
Desktop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome
Supported Phones & Tablets:
All devices
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]